Your browser doesn't support javascript.
loading
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
Janku, Filip; Beom, Seung-Hoon; Moon, Yong Wha; Kim, Tae Won; Shin, Young G; Yim, Dong-Seok; Kim, Gun Min; Kim, Hyo Song; Kim, Sun Young; Cheong, Jae-Ho; Lee, Young Woo; Geiger, Barb; Yoo, Sanghee; Thurston, Archie; Welsch, Dean; Rudoltz, Marc S; Rha, Sun Young.
Afiliación
  • Janku F; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Beom SH; Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.
  • Moon YW; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim TW; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, Seongnam, South Korea.
  • Shin YG; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Yim DS; Institute of Drug Research and Development, College of Pharmacy, Chungnam National University, Daejeon, South Korea.
  • Kim GM; Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Kim HS; Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.
  • Kim SY; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
  • Cheong JH; Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.
  • Lee YW; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
  • Geiger B; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Yoo S; Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea.
  • Thurston A; Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
  • Welsch D; ImmunoMet Therapeutics, Inc, Houston, TX, USA.
  • Rudoltz MS; ImmunoMet Therapeutics, Inc, Houston, TX, USA.
  • Rha SY; ImmunoMet Therapeutics, Inc, Houston, TX, USA.
Invest New Drugs ; 40(5): 1001-1010, 2022 Oct.
Article en En | MEDLINE | ID: mdl-35802288
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Invest New Drugs Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Invest New Drugs Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos